CG MedTech, a South Korea–based orthopedic implant company, has acquired a 90 percent stake in Germany-based Solendos, a developer of spine endoscopy equipment, in a move aimed at strengthening its capabilities in minimally invasive spine surgery.
Announced on Monday, the acquisition brings an endoscopic camera platform and related radiofrequency (RF) surgical devices into CG MedTech’s spine portfolio, which has primarily focused on implants such as cages and screws, along with the bone graft substitute NOVOSIS developed by its parent company, CGBIO.
According to CG MedTech, the deal completes its “diagnosis–surgery–regeneration” vertical integration strategy, enabling the company to offer a comprehensive spine surgery solution that combines visualization, surgical instruments, implant placement, and bone regeneration technologies.
Expanding in Biportal Endoscopic Spine Surgery
Solendos specializes in endoscopy systems designed for unilateral biportal endoscopy (UBE), also known as biportal endoscopic spine surgery (BESS)—a technique gaining global adoption as surgeons increasingly seek less invasive approaches to spinal procedures.
CG MedTech said Solendos’ spine endoscopy system and related instrument sets have already received U.S. FDA clearance, providing the combined group with a regulatory foothold as it targets the U.S. ambulatory surgery center market and the rapidly expanding biportal spine surgery segment.
The company plans to leverage the FDA-cleared platform to accelerate commercialization in the United States, while also advancing overseas expansion of its UniSpace cage and preparing U.S.-based clinical work to support a future FDA submission for NOVOSIS.
Integrating AI and Building a Training Ecosystem
Beyond expanding its hardware offerings, CG MedTech emphasized the strategic importance of bringing endoscopy technology in-house to enable closer integration with its AI-based surgical assistance software. The software is designed to recognize and label anatomical structures—such as the spine, nerves, and muscles—in real time from endoscopic video, supporting intraoperative decision-making.
The company also aims to move beyond device sales by developing a training ecosystem for endoscopic spine surgery, describing the technique as highly skill-intensive. CG MedTech outlined plans to create a virtuous cycle linking device adoption, surgeon education, and implant utilization.
As part of this initiative, the company is preparing education and hands-on training programs tied to a planned Daewoong surgical skills center at Daewoong Pharmaceutical’s Magok C&D (Connected & Development) Center, which is scheduled to open in July 2026.
With this acquisition, CG MedTech is positioning itself to play a broader role in the evolution of minimally invasive spine surgery by combining visualization technology, implants, regenerative solutions, artificial intelligence, and surgeon training into a unified platform.
Source: Korea Biomedical Review (KBR)